Coverage for GLP-1 Drug Class (Commercial & Medicare) — Prior Authorization and Documentation Requirements
Customize your policy alerts
Sign up for all Florida Blue policy alerts
Know when Florida Blue releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Florida Blue commercial and Medicare pharmacy coverage and prior authorization requirements for GLP-1 class drugs, limiting coverage to FDA-approved indications for type 2 diabetes and specifying documentation and drug-specific coverage rules for affected members and providers.
Commercial prior authorization criteria now require clinical documentation of a type 2 diabetes diagnosis and documentation that the patient tried and failed metformin, metformin combinations, or insulin.
Victoza is excluded from coverage for commercial plans effective April 1, 2024, with continuation allowed for current members until July 1, 2024.
Medicare and Florida Blue do not cover GLP-1 medications when requested for weight loss/management; such requests will be denied.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.